EuBiologics Co. Ltd. (206650)
KOSDAQ · Korea · prices in KRW · close of 20 Oct 2026
Key indicators
| Last close | KRW 7,870.00 |
|---|---|
| 52-week range | 6,950.00 – 17,700.00 |
| Return, 1 month / 3 months | −6.3% / −3.7% |
| Return, 1 year / 3 years | −40.4% / −24.0% |
| Trend | Below its 200-day average |
| RSI (14) | 39 |
| Volatility (1 year) | 47.7% |
| Worst drawdown (1 year) | -54.4% |
| Average daily value traded | 1,047.76M KRW |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
EuBiologics is a South Korean biopharmaceutical company that develops and manufactures vaccines. Its main product is an oral cholera vaccine, which is supplied to public health programmes and international procurement agencies for use in outbreak response and prevention. The company also works on other vaccine candidates and contract manufacturing for partners. It is based in South Korea, where it carries out research, development and production of its vaccine products for customers and health organisations around the world.
EuBiologics Co. Ltd. trades under the code 206650 on the KOSDAQ in Korea, with its price quoted in South Korean won (KRW). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
EuBiologics Co. Ltd. (206650) trades on the KOSDAQ in Korea. It last closed at KRW 7,870.00 on 20 October 2026.
Its price-based Market X-Ray is 49 out of 100 (a weak price profile), ranking 987 of 1,831 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 40.4% and over the last three months it fell 3.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on KOSDAQ
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 36 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -27.4% | ||
| From 52-week high | -51.4% | ||
| Momentum | 33 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -3.7% | ||
| 6-month return | -39.9% | ||
| 12-month return, skipping the last month | -36.4% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 47.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -54.4% | ||
| Liquidity | 70 · Fair | Moderate trading activity. | |
| Average daily value traded | 1,047.76M KRW | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −3.3% |
|---|---|
| 1 month | −6.3% |
| 3 months | −3.7% |
| 6 months | −39.9% |
| 1 year | −40.4% |
| 3 years | −24.0% |
| 5 years | – |
Signals
| 50-day / 200-day average | 8,595.20 / 10,833.75 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 355.53 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on KOSDAQ; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.